Streetbeat News

Revenues

MULN

Mullen Automotive has announced that Bollinger Motors, which it owns, has received orders for 40 B4, Class 4 electric trucks. The orders are valued at approximately $6 million.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:31 pm

RVYL

RYVYL projects its 2024 revenue to be between $95M and $100M, representing a 67% increase from its 2023 revenue figures.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:03 pm

RVYL

RYVYL, Inc. has announced its expectation for 2023 revenue to increase by over 90% compared to 2022, signaling significant growth for the company.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 2:02 pm

ASUR

Asure Software (NASDAQ:ASUR) has received mixed analyst ratings over the past three months, with 3 bullish, 1 somewhat bullish, and 1 indifferent. The average 12-month price target is $15.4, a slight increase from the previous $15.00. Analysts from Needham, Stifel, Lake Street, and Barrington Research have provided ratings and price targets, with Needham maintaining a 'Buy' rating with a $20.00 target. Asure Software provides cloud-based HCM solutions and has shown a 33.93% revenue growth rate over 3 months but has a net margin of -7.52% and ROE of -1.3%, indicating profitability challenges.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 2:00 pm

MTB

Over the past three months, four analysts have provided varied opinions on M&T Bank (NYSE:MTB), with recent ratings showing two somewhat bullish and two indifferent stances. The average 12-month price target for MTB has risen to $158.75, a 3.42% increase from the previous target. Analysts from RBC Capital, Barclays, Deutsche Bank, and Morgan Stanley have maintained or raised their ratings and price targets. M&T Bank's financials show a solid revenue growth of 4.16%, an exceptional net margin of 28.43%, and strong ROE and ROA figures, indicating robust financial health and management.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 2:00 pm

SNV

Analysts have provided mixed ratings for Synovus Financial Corp (NYSE:SNV) with an updated average 12-month price target of $40.2, reflecting a 14.24% increase from the previous target. The ratings include 'Outperform', 'Strong Buy', 'In-Line', 'Equal-Weight', 'Neutral', and 'Buy'. Synovus offers a range of banking services and faces challenges such as below-average market capitalization, revenue decline, and lower net margin, ROE, and ROA compared to industry averages. However, its lower debt-to-equity ratio suggests a healthier balance between debt and equity.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 2:00 pm

SPT

Sprout Social (NASDAQ:SPT) has received mixed analyst ratings over the past three months, with 1 bullish and 4 somewhat bullish ratings. The average 12-month price target is $68.8, up from $57.75, with a high estimate of $75.00 and a low of $58.00. Analysts from Needham, Barclays, Cantor Fitzgerald, Piper Sandler, and Keybanc have adjusted their ratings and price targets, reflecting their views on the company's market performance and financial indicators. Sprout Social's financials show a revenue growth rate of 30.97% as of September 30, 2023, but it has a net margin of -26.91% and an ROE of -15.65%, indicating potential profitability and efficiency challenges.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 2:00 pm

ALL

In the last three months, 13 analysts have provided diverse ratings for Allstate (NYSE:ALL), with a trend towards bullish sentiment. The average 12-month price target is $159.69, up 15.57% from the previous $138.18. Analysts from firms like BMO Capital, UBS, TD Cowen, Goldman Sachs, Jefferies, Morgan Stanley, HSBC, Raymond James, Piper Sandler, and Roth MKM have raised their price targets, reflecting optimism about Allstate's future performance. Despite this, Allstate's financial indicators such as revenue growth, net margin, ROE, ROA, and debt management show mixed results, with some metrics below industry averages.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 2:00 pm

VXRT

Vaxart, Inc. has been awarded a $9.27 million BARDA Project NextGen award to prepare for a Phase 2b clinical study of its oral pill XBB COVID-19 vaccine candidate. The study will compare the vaccine to an approved mRNA vaccine. The funding is part of a $5 billion HHS initiative to develop vaccines offering broader, more durable protection against COVID-19. Vaxart's vaccine aims to address needle-phobia and provide a cross-reactive response to various COVID variants by triggering both systemic and mucosal immune responses.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 1:31 pm

GENI

Genius Sports (NYSE:GENI) received varied analyst ratings in the last quarter, with 4 bullish ratings. Over the past 30 days, there has been a shift in sentiment with a decrease in the average price target by 20%, now averaging $10.00 with a high of $12.00 and a low of $9.00. Analysts from Needham and Craig-Hallum have maintained or lowered their price targets. Genius Sports, a B2B provider for the sports and betting industries, has seen a 29.34% revenue growth but struggles with profitability and efficiency, as indicated by below-average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 1:01 pm